<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34234679</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1663-9812</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in pharmacology</Title>
          <ISOAbbreviation>Front Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rufinamide-Loaded Chitosan Nanoparticles in Xyloglucan-Based Thermoresponsive <i>In Situ</i> Gel for Direct Nose to Brain Delivery.</ArticleTitle>
        <Pagination>
          <StartPage>691936</StartPage>
          <MedlinePgn>691936</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">691936</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2021.691936</ELocationID>
        <Abstract>
          <AbstractText>In 2004, the US FDA approved Rufinamide, an anti-epileptic drug under the brand name Banzel<sup>®</sup>. In 2015, Banzel<sup>®</sup> received approval for its use in pediatric patients (ages 1-4 years). Rufinamide shows low oral bioavailability due to a low dissolution rate resulting in less of the drug reaching the brain. This has led to the high dose and dosing frequency of Rufinamide. In this work, using the principle of design of experiments (DoE), we have formulated Rufinamide-loaded chitosan nanoparticles and suspended them in a solution of a thermoresponsive polymer-tamarind seed xyloglucan to form a nasal <i>in situ</i> gel for direct nose to brain delivery of Rufinamide. The nanoparticles were characterized for particle size, entrapment efficiency, zeta potential, and physical stability. The <i>in situ</i> gel formulations were characterized for rheological properties, stability, and <i>in vivo</i> plasma and brain pharmacokinetics. Pharmacokinetic parameters were computed for aqueous suspension of nanoparticles and <i>in situ</i> gelling formulation for nanoparticles and compared with the pharmacokinetic parameters of an aqueous suspension of plain Rufinamide. The percentage of direct transport efficiency (% DTE) and direct transport percentage (%DTP) values were calculated for all the formulations. The optimized nanoparticle formulation showed a size of 180 ± 1.5 nm, a zeta potential of 38.3 ± 1.5 mV, entrapment efficiency of 75 ± 2.0%, and drug loading of 11 ± 0.3%. The <i>in situ</i> gelling formulation of nanoparticles showed a solution to the gel transition temperature of 32°C. The %DTE values for aqueous suspension of nanoparticles and <i>in situ</i> gelling formulation for nanoparticles were 988.5 and 1177.3 and the %DTP values were 86.06 and 91.5 respectively.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Dalvi, Ravi and Uppuluri.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dalvi</LastName>
            <ForeName>Avantika</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BITS-Pilani, Hyderabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ravi</LastName>
            <ForeName>Punna Rao</ForeName>
            <Initials>PR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BITS-Pilani, Hyderabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uppuluri</LastName>
            <ForeName>Chandra Teja</ForeName>
            <Initials>CT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BITS-Pilani, Hyderabad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Pharmacol</MedlineTA>
        <NlmUniqueID>101548923</NlmUniqueID>
        <ISSNLinking>1663-9812</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rufinamide</Keyword>
        <Keyword MajorTopicYN="N">chitosan nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">nose to brain delivery</Keyword>
        <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="N">thermoresponsive gel</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34234679</ArticleId>
        <ArticleId IdType="pmc">PMC8257053</ArticleId>
        <ArticleId IdType="doi">10.3389/fphar.2021.691936</ArticleId>
        <ArticleId IdType="pii">691936</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Aaberg K. M., Gunnes N., Aaberg N., Bakken I. J., Lund Søraas C., Berntsen A., et al.  (2017). Incidence and Prevalence of Childhood Epilepsy: A Nationwide Cohort Study. Pediatrics
139 (5), e20163908. 10.1542/peds.2016-3908
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2016-3908</ArticleId>
            <ArticleId IdType="pubmed">28557750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aderibigbe B. A., Naki T. (2019). Chitosan-Based Nanocarriers for Nose to Brain Delivery. Appl. Sci.
9 (11), 2219. 10.3390/app9112219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/app9112219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dalvi A. V., Ravi P. R, Uppuluri C. T., Mahajan R. R., Katke S. V., Deshpande V. S. (2021). Thermosensitive Nasal In Situ Gelling Systems of Rufinamide Formulated Using Modified Tamarind Seed Xyloglucan for Direct Nose-To-Brain Delivery: Design, Physical Characterization, and In Vivo Evaluation. J. Pharm. Investig.
51, 199–211. 10.1007/s40005-020-00505-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40005-020-00505-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dalvi A. V., Uppuluri C. T., Bommireddy E. P., Ravi P. R. (2018)., Design of Experiments-Based RP - HPLC Bioanalytical Method Development for Estimation of Rufinamide in Rat Plasma and Brain and its Application in Pharmacokinetic Study. J. Chromatogr. BAnalyt. Technol. Biomed. Life. Sci
1102-1103, 74–82. 10.1016/j.jchromb.2018.10.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2018.10.014</ArticleId>
            <ArticleId IdType="pubmed">30380466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ema (2011). No Title. Available at: https://www.ema.europa.eu/en/documents/variation-report/inovelon-h-c-660-x-17-epar-assessment-report-extension_en.pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
Giunchedi P., Gavini E., Bonferoni M. C. (2020). Nose-to-Brain Delivery. Pharmaceutics
12, 138. 10.3390/pharmaceutics12020138
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics12020138</ArticleId>
            <ArticleId IdType="pmc">PMC7076467</ArticleId>
            <ArticleId IdType="pubmed">32041344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Illum L. (2000). Transport of Drugs from the Nasal Cavity to the Central Nervous System. Eur. J. Pharm. Sci.
11, 1–18. 10.1016/S0928-0987(00)00087-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0928-0987(00)00087-7</ArticleId>
            <ArticleId IdType="pubmed">10913748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Martínez-Ibarra D. M., Sánchez-Machado D. I., López-Cervantes J., Campas-Baypoli O. N., Sanches-Silva A., Madera‐Santana T. J.(2019). Hydrogel Wound Dressings Based on Chitosan and Xyloglucan: Development and Characterization. J. Appl. Polym. Sci.
136 (12), 1–10. 10.1002/app.47342
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/app.47342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
MedlinePlus (2020). “Lennox Gastaut Syndrome” 2020. Available at: https://medlineplus.gov/genetics/condition/lennox-gastaut-syndrome/
</Citation>
        </Reference>
        <Reference>
          <Citation>
Perucca E., Cloyd J., Critchley D., Fuseau E. (2008). Rufinamide: Clinical Pharmacokinetics and Concentrationresponse Relationships in Patients with Epilepsy. Epilepsia
49 (7), 1123–1141. 10.1111/j.1528-1167.2008.01665.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2008.01665.x</ArticleId>
            <ArticleId IdType="pubmed">18503564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rassu G., Soddu E., Cossu M., Gavini E., Giunchedi P., Dalpiaz A. (2016). Particulate Formulations Based on Chitosan for Nose-To-Brain Delivery of Drugs. A Review. J. Drug Deliv. Sci. Techn.
32, 77–87. 10.1016/j.jddst.2015.05.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jddst.2015.05.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rázga F., Vnuková D., Némethová V., Mazancová P., Lacík I. (2016). Preparation of Chitosan-TPP Sub-micron Particles: Critical Evaluation and Derived Recommendations. Carbohydr. Polym.
151, 488–499. 10.1016/j.carbpol.2016.05.092
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.carbpol.2016.05.092</ArticleId>
            <ArticleId IdType="pubmed">27474593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saikia C., Gogoi P. (2015). Chitosan: A Promising Biopolymer in Drug Delivery Applications. J. Mol. Genet. Med.
s4 (July). 10.4172/1747-0862.s4-006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/1747-0862.s4-006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Turner P. V., Brabb T., Pekow C., Vasbinder M. A. (2011). Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider. J. Am. Assoc. Lab. Anim. Sci.
50 (5), 600–613. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3189662</ArticleId>
            <ArticleId IdType="pubmed">22330705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ways, Twana Mohammed M., Lau W. M., Khutoryanskiy V. V. (2018). Chitosan and its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers
10 (3), 267. 10.3390/polym10030267
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/polym10030267</ArticleId>
            <ArticleId IdType="pmc">PMC6414903</ArticleId>
            <ArticleId IdType="pubmed">30966302</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
